Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 220Head and Neck Neoplasms 172Carcinoma, Non-Small-Cell Lung 104Melanoma 63Neoplasms 56Colorectal Neoplasms 55Uterine Cervical Neoplasms 53Ovarian Neoplasms 50Stomach Neoplasms 48Neoplasm Metastasis 46Breast Neoplasms 46Triple Negative Breast Neoplasms 45Lung Neoplasms 44Carcinoma, Renal Cell 40Esophageal Neoplasms 37Nasopharyngeal Carcinoma 33Endometrial Neoplasms 33Pancreatic Neoplasms 32Thyroid Neoplasms 30Prostatic Neoplasms 26Carcinoma, Squamous Cell 26Sarcoma 25Colonic Neoplasms 24Urinary Bladder Neoplasms 23Small Cell Lung Carcinoma 23Oropharyngeal Neoplasms 23Carcinoma, Transitional Cell 23Carcinoma 22Salivary Gland Neoplasms 20Nasopharyngeal Neoplasms 20

Interventions

pembrolizumab 1epacadostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Microsatellite Instability × Head & Neck × Clear all
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡